Potassium-sparing agents during diuretic therapy in hypertension

Area of Science:

• Pharmacology
• Nephrology
• Cardiovascular Medicine

Background:

• Diuretic therapy for hypertension can lead to potassium depletion.
• Potassium-sparing agents are used to mitigate this side effect.
• Accurate assessment of potassium balance is crucial.

Purpose of the Study:

• To evaluate the efficacy of three potassium-sparing agents in hypertensive patients undergoing diuretic therapy.
• To assess the impact of these agents on total exchangeable potassium (K(E)).
• To determine the reliability of plasma potassium levels in reflecting K(E) restoration.

Main Methods:

• Serial measurements of total exchangeable potassium (K(E)) were performed.
• Hypertensive subjects received oral diuretic therapy for 4 to 12 weeks.
• Three agents were tested: Triamterene, Spironolactone, and Slow-K.

Main Results:

• Triamterene (50 mg twice daily) showed limited efficacy.
• Spironolactone (25 mg twice daily) significantly reduced potassium loss.
• Slow-K (32 mEq daily) completely reversed pre-existing potassium deficits.
• Plasma potassium levels did not accurately indicate the extent of K(E) restoration.

Conclusions:

• Spironolactone and Slow-K are effective in preserving potassium balance during diuretic treatment.
• Triamterene may be less effective at the tested dosage.
• Plasma potassium monitoring alone is insufficient for assessing total body potassium status.